<DOC>
	<DOCNO>NCT01289990</DOCNO>
	<brief_summary>This study investigate efficacy long term safety tolerability BI 10773 type 2 diabetic patient .</brief_summary>
	<brief_title>Safety Efficacy Empagliflozin ( BI 10773 ) Sitagliptin Versus Placebo Over 76 Weeks Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients complete entire treatment period precede doubleblind trial 1245.19 , 1245.20 1245.23 without rescue therapy . 2 . Signed date write informed consent date Visit 1 accordance Good Clinical Practice local legislation . Exclusion criterion : 1 . Patient meet one withdrawal criterion treatment period previous trial 1245.19 , 1245.20 1245.23 . 2 . Indication liver disease , define serum level either alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase 3 x upper limit normal determine last visit precede trial . 3 . Impaired renal function define glomerular filtration rate &lt; 30 ml/min ( severe renal impairment , Modification Diet Renal Disease formula ) determine last visit precede trial . 4 . Contraindications sitagliptin , pioglitazone , metformin sulfonylurea accord local label , start trial participation 1245.19 , 1245.20 1245.23 5 . Premenopausal woman ( last menstruation &lt; = 1 year prior informed consent ) nursing pregnant childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include tubal ligation , transdermal patch , intra uterine devices/systems , oral , implantable injectable contraceptive , sexual abstinence ( acceptable local authority ) , double barrier method vasectomise partner . 6 . Alcohol drug abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake . 7 . Participation another trial investigational drug within 30 day prior inform consent ( except 1245.19 , 1245.20 1245.23 ) . 8 . Any clinical condition would jeopardize patient 's safety participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>